ArticleJournal of mid-life health
Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, has demonstrated robust weight loss and glycemic benefits in randomized controlled trials. However, real-world data comparing its effectiveness and tolerability in obese adults with and without type 2 diabetes (T2D) are limited. The present study aimed to evaluate the real-world short-term effectiveness and safety of tirzepatide in promoting weight loss among obese or overweight adults with and without T2D. Methods: This was a 12-week, prospective, observational cohort study involving 93 adults (70 individuals without diabetes and 23 individuals with T2D) receiving tirzepatide at a tertiary care center. The primary outcome was change in body weight. The secondary outcomes included changes in body mass index (BMI), waist circumference (WC), glycemic parameters (in individuals with T2D only), responder thresholds (≥5%, ≥10%, and ≥15% weight loss), and adverse events (AEs). Between-group comparisons were adjusted using multivariable regression and 1:3 propensity score matching. Results: Both the groups experienced significant reductions in weight, BMI, and WC (all Conclusion: Tirzepatide produced meaningful weight loss in both T2D and non-T2D obese adults, with additional glycemic improvements in T2D. Individuals without diabetes were more likely to achieve ≥10% weight loss, while tolerability remained acceptable in both the groups. These real-world findings support tirzepatide's role in individualized obesity and metabolic disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.